y p o c t o
play

Y P O C T O Neurological Applications of N Transcranial - PowerPoint PPT Presentation

Y P O C T O Neurological Applications of N Transcranial Magnetic Stimulation O D Mouhsin Shafi, MD/PhD E Berenson-Allen Center for Noninvasive S Brain Stimulation A BIDMC, Harvard Medical School E L P Y P Overview of Talk O


  1. Y P O C T O Neurological Applications of N Transcranial Magnetic Stimulation O D Mouhsin Shafi, MD/PhD E Berenson-Allen Center for Noninvasive S Brain Stimulation A BIDMC, Harvard Medical School E L P

  2. Y P Overview of Talk O C • FDA-Approved Indications T – Presurgical Motor & Language Mapping O – Migraine N • Diagnosis / Prognosis O D – Motor outcome after stroke, Epilepsy, Vegetative state E • Therapeutics S A – Review of results across neurologic indications E L P

  3. Y P Overview of Talk O C • FDA-Approved Indications T – Presurgical Motor & Language Mapping O – Migraine N • Diagnosis / Prognosis O D – Motor outcome after stroke, Epilepsy, Vegetative state E • Therapeutics S A – Review of results across neurologic indications E L P

  4. Y P Motor / Language Mapping O C T O • FDA approval of Nexstim N NBS device for: – Mapping of the primary O motor cortex D – Localization of cortical areas E that do NOT contain S essential speech function A – For pre-procedural planning E L P Picht 2011 Neurosurgery

  5. Y P O Motor Cortical Output Mapping C T O N O D E S A E L P Nagib et al. Neurosurg Clin 2011

  6. Y P O Motor Cortical Output Mapping C Comparing Noninvasive and Invasive Mapping T O N O D E S A E L P Najib et al. Neurosurg Clin 2011

  7. Y Motor mapping P O • Comparing nTMS to Direct C Cortical Stimulation (DCS): – Mean distance between nTMS T & DCS hotspots was 7.83 +/- O 1.18 mm for APB (95% CI 5.36 to 10.36 cm) N – nTMS and DCS hotspots were in same gyrus for all patients O D E S A E L P Picht 2011 Neurosurgery

  8. Y P nTMS vs fMRI O C • Several studies have evaluated accuracy of motor mapping with nTMS vs fMRI (with DCS as gold standard) T O – Forster 2011, Neurosurgery : 10 pts, mean distance to DCS hotspot 10.5 +/- 5. 7 mm for nTMS vs 15.0 +/- 7.6 mm for fMRI N – Mangraviti 2013, Neurol Sci : 7 patients, mean distance to DCS O hotspot 8.5 +/- 4.6 mm for nTMS vs 12.9 +/- 5.7 mm for fMRI D Coburger 2013, Neurosurg Rev : 30 E patients; all 30 completed nTMS, S whereas only 23 completed fMRI. A Authors binned results into 4 E levels, where 1 is most accurate, 4 L is least accurate P

  9. Y P Motor mapping w/ nTMS improves outcome? O C • Krieg 2014 Neuro-Oncology : Compared outcomes in 100 consecutive patients bw 2010-2013 vs 100 historical T controls without nTMS from immediately prior period O – All patients underwent intraoperative MEP monitoring as well N – Craniotomy size significantly smaller in nTMS group O – 12 pts in nTMS group improved, vs only 1 in control group D – Residual tumor in 22% of nTMS group vs 42% of controls E S A E L P

  10. Y P Motor mapping w/ nTMS improves outcome? O C • Frey 2014 Neurosurgery : Compared outcomes in 250 consecutive pts from 2007 – 2012 with 115 controls T from 2005-2007 O – 165 cases with intraoperative stimulation mapping, nTMS N location of primary motor cortex confirmed in all cases. O – In 82 cases with navigated intraop stim, mean distance bw D nTMS and DCS hotspot was 6.2 mm (range 0.4 – 14.8 mm) – Gross total resection achieved in 59% of nTMS group vs only E 42% of historical control, with no change in post-op deficits S A Progression-free survival E significantly higher in nTMS group than in control group L P (15.5 vs 12.4 months), although no change in overall survival

  11. Y P Motor mapping w/ nTMS improves outcome? O C • Krieg 2015 BMC Cancer : Compared nTMS outcomes in 70 patients with high-grade (grade III or grade IV) glioma T vs 70 historical controls O – Trend towards decreased permanent weakness in nTMS group N – Greater survival in grade III tumor patients in nTMS group due O to greater percentage achieving gross total resection (but not D present across all patients) – Higher survival rate at 3, 6, 9 and 12 months in nTMS group E S A E L P

  12. Y P And resecting nTMS motor areas is bad O C • Moser 2017 Neurosurgery : Evaluated motor outcomes in 43 patients with Rolandic or T O prerolandic gliomas undergoing nTMS N – 31 patients had nTMS motor points in prerolandic O regions - 13/43 underwent resection D of nTMS-positive points; E 8/13 suffered permanent S paresis A - 30/43 did not undergo any E resection of nTMS-positive L points; only 1/30 suffered P permanent paresis

  13. Y P Language mapping O C • Picht 2013, Neurosurgery : Evaluated nTMS and DCS responses during language mapping in 20 patients with T O tumors close to left-sided language areas N O D E S A E L P

  14. Y P Language mapping … O C T O • A subsequent study (Tarapore 2013, N NeuroImage ) also O demonstrated high D negative predictive value, with E improved specificity S A E L P

  15. Y Compared with fMRI and DCS P O C Ille 2015a, b: T Compared language O mapping results from N rTMS (C) and fMRI (D) O with those from DCS D (B) E S A E L P

  16. Y P And may have beneficial effects O C T O N O D E S A E L P Early language deficits decreased Craniotomy size smaller w/ TMS Sollman 2015

  17. Y P Preoperative mapping using nTMS O C • Review paper: Clinical Neurophysiology 2016 T O N O D E • Operationalization and workflow: World Neurosurgery S A 2017 E L P

  18. Y P Abortive therapy migraine O C • FDA approval for the SpringTMS single-pulse T portable TMS system obtained for abortive therapy O of migraine with aura N – 2 pulses of TMS administered approximately 30s apart to occipital region O D E S A E L P Image from www.medgadget.com

  19. Y P Efficacy in acute migraine O C • Randomized 201 patients with migraine with aura, 1-8 episodes per month, aura for at least 30% of episodes T O – 201 randomized, 164 had migraines and treated N • Higher pain-free response rates after 2 hours (39% in verum vs 22% in sham), sustained at 24 and 48 hours O D HOWEVER, a number of secondary endpoints (patients E who achieved no or mild pain 2h S after treatment, use of rescue A drugs, consistency of pain relief, E global assessment of relief) L showed no significant differences P Lipton, Lancet Neurology 2010

  20. Y P Overview of Talk O C • FDA-Approved Indications T – Presurgical Motor & Language Mapping O – Migraine N • Diagnosis / Prognosis O D – Motor outcome after stroke, Epilepsy, Vegetative state E • Therapeutics S A – Review of results across neurologic indications E L P

  21. Y MEPs predict functional recovery after P acute stroke O C T O N O D E S A E L P Stinear 2012, Brain

  22. Y Paired-pulse measures identify cortical P O hyperexcitability in Epilepsy C T O N O D E S A Paired-pulse measures suggest altered excitation E / inhibition balance in patients with newly- L diagnosed epilepsy compared to healthy controls P Badawy 2007 Ann Neurol

  23. Y P And predict response to medications O C TMS-EMG paired-pulse measures normalize in T patients who respond to O meds; no such changes seen N those with ongoing seizures O D E S A E L P Epilepsy patients, before meds Badawy 2010, Ann Neurol Epilepsy patients, after meds Normal controls

  24. Y P Diagnosis of Persistent Vegetative vs O Minimally Conscious State Casali 2013, Science Trans Med C T O N O D E S A E L Decreased complexity of evoked response in subjects with loss of P consciousness due to any etiology, and in patients with vegetative versus minimally conscious versus locked-in states M /F

  25. Y P Overview of Talk O C • FDA-Approved Indications T – Presurgical Motor & Language Mapping O – Migraine N • Diagnosis / Prognosis O D – Motor outcome after stroke, Epilepsy, Vegetative state E • Therapeutics S A – Review of results across neurologic indications E L P

  26. Y P Theraputic effects? O C • rTMS has been studied as a therapeutic modality in different neurologic conditions including T – Epilepsy O – Migraine prevention N – Motor rehabilitation after stroke O – Cognitive rehabilitation in post-stroke aphasia, post- stroke neglect and Alzheimer’s Disease D – Movement Disorders (primarily Parkinson’s) E – Chronic Pain S – Tinnitus A • However, FDA indication has not been yet obtained E for any of these (multi-center trials currently L underway in several disease conditions) P

  27. Y P Key References O C • Handbook of Clinical Neurology T – Volume 116, Pages 2-763, 2013; Edited by Andres O Lozano and Mark Hallett N – Overview of Deep Brain Stimulation and Noninvasive O Brain Stimulation across spectrum of neurologic D diseases • Lefaucheur et al, Clinical Neurophysiology 2014 E S – Recent evidence-based review/guidelines on A therapeutic use of rTMS in neurologic and psychiatric E diseases L P

  28. Y Principles for successful intervention P O with TMS/tDCS C T • Known brain region or network O • Known goal to enhance or decrease activity of N that network O • Target can be engaged by stimulation D intervention E S A E L P

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend